Humanskeletal musclexenograft as anewpreclinical model for muscle disorders

Human Molecular Genetics

Volumn 23, Issue 12, 2014, Pages 3180-3188

  Zhang, Yuanfan ^a,b   King, Oliver D ^d   Rahimov, Fedik ^e   Jones, Takako I ^d   Ward, Christopher W ^g   Kerr, Jaclyn P ^h   Liu, Naili ^a   Emerson, Charles P ^d   Kunkel, Louis M ^e,f   Partridge, Terence A ⁱ   Wagner, Kathryn R ^a,b,c  

^a KENNEDY KRIEGER INSTITUTE   (United States)

^b Program in Cellular and Molecular Medicine   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e Division of Genetics   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF NURSING   (United States)

^h UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

ⁱ CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM PHOSPHATE COTRANSPORTER 2B; SPECTRIN; GENETIC MARKER;

ANIMAL EXPERIMENT; ARTICLE; BASEMENT MEMBRANE; CALCIUM TRANSPORT; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FEASIBILITY STUDY; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC REGULATION; HUMAN; HUMAN TISSUE; MBD3L5 GENE; MOUSE; MUSCLE BIOPSY; MUSCLE DISEASE; MUSCLE REGENERATION; MYH8 GENE; NEUROMUSCULAR SYNAPSE; NONHUMAN; NORMAL HUMAN; PERONEUS NERVE; PRAMEF1 GENE; PRAMEF6 GENE; PRIORITY JOURNAL; SKELETAL MUSCLE; SKELETAL MUSCLE XENOGRAFT; TRIM43 GENE; TRIM49 GENE; TRIM51 GENE; UPREGULATION; VALIDITY; XENOGRAFT; ZSCAN4 GENE; ANIMAL; DISEASE MODEL; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKER; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; TRANSPLANTATION;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED NOD; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL;

EID: 84901354846     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu028     Document Type: Article

References (42)

1. Duan, D. (2011) Duchenne muscular dystrophy gene therapy: lost in translation? Res. Rep. Biol., 2011, 31-42.
2. Partridge, T.A. (2013) The mdx mouse model as a surrogate for Duchenne muscular dystrophy. FEBS J., 280, 4177-4186.
3. Griggs, R.C., Moxley, R.T. III, Mendell, J.R., Fenichel, G.M., Brooke, M.H., Pestronk, A. and Miller, J.P. (1991) Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch. Neurol., 48, 383-388.
4. Mendell, J.R., Moxley, R.T., Griggs, R.C., Brooke, M.H., Fenichel, G.M., Miller, J.P., King, W., Signore, L., Pandya, S., Florence, J. et al. (1989) Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. New Engl. J. Med., 320, 1592-1597.
5. Sali, A., Guerron, A.D., Gordish-Dressman, H., Spurney, C.F., Iantorno, M., Hoffman, E.P. and Nagaraju, K. (2012) Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse. PLoS ONE, 7, e34204.
6. Orphanet: an online database of rare disease and orphan drugs. (2013). http://www.orpha.net/, Accessed 21 October 2013.
7. van Deutekom, J.C., Wijmenga, C., van Tienhoven, E.A., Gruter, A.M., Hewitt, J.E., Padberg, G.W., van Ommen, G.J., Hofker, M.H. and Frants, R.R. (1993) FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum. Mol. Genet., 2, 2037-2042.
8. Wijmenga, C., Hewitt, J., Sandkuijl, L.A., Clark, L.N., Wright, T.J., Dauwerse, H.G., Gruter, A.M., Hofker, M.H., Moerer, P., Williamson, R. et al. (1992) Chromosome 4q DNA rearrangements associated with facioscpulohumeral muscular dystrophy. Nat. Genet., 2, 26-30.
9. Statland, J.M. and Tawil, R. (2011) Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions. Curr. Opin. Neurol., 24, 423-428.
10. Lemmers, R.J., Wohlgemuth, M., van der Gaag, K.J., van der Vliet, P.J., van Teijlingen, C.M., de Knijff, P., Padberg, G.W., Frants, R.R. and van der Maarel, S.M. (2007) Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. Am. J. Hum. Genet., 81, 884-894.
11. Lemmers, R.J., van der Vliet, P.J., Klooster, R., Sacconi, S., Camanõ, P., Dauwerse, J.G., Snider, L., Straasheijm, K.R., van Ommen, G.J., Padberg, G.W. et al. (2010) A unifying genetic model for facioscapulohumeral muscular dystrophy. Science, 329, 1650-1653.
12. Snider, L., Geng, L.N., Lemmers, R.J., Kyba, M., Ware, C.B., Nelson, A.M., Tawil, R., Filippova, G.N., van der Maarel, S.M., Tapscott, S.J. et al. (2010) Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet., 6, e1001181.
13. Adams, J. (2002) Development of the proteasome inhibitor PS-341. Oncologist, 7, 9-16.
14. Pegram, M. and Ngo, D. (2006) Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptinw): a case study. Adv. Drug Deliv. Rev., 58, 723-734.
15. Benchaouir, R., Meregalli, M., Farini, A., D'Antona, G., Belicchi, M., Goyenvalle, A., Battistelli, M., Bresolin, N., Bottinelli, R., Garcia, L. et al. (2007) Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell, 1, 646-657.
16. Cooper, R.N., Irintchev, A., Di Santo, J.P., Zweyer, M., Morgan, J.E., Partridge, T.A., Butler-Browne, G.S., Mouly, V. and Wernig, A. (2001) A new immunodeficient mouse model for human myoblast transplantation. Hum. Gene Ther., 12, 823-831.
17. Meng, J., Adkin, C.F., Xu, S.W., Muntoni, F. and Morgan, J.E. (2011) Contribution of human muscle-derived cells to skeletal muscle regeneration in dystrophic host mice. PLoS ONE, 6, e17454.
18. Riederer, I., Negroni, E., Bencze, M., Wolff, A., Aamiri, A., Di Santo, J.P., Silva-Barbosa, S.D., Bulter-Browne, G., Savino, W. and Mouly, V. (2012) Slowing down differentiation of engrafted human myoblasts into immunodeficient mice correlates with increased proliferation and migration. Mol. Ther., 20, 146-154.
19. Morgan, J.E., Coulton, G.R. and Partridge, T.A. (1989) Mdx muscle grafts retain the mdx phenotype in normal hosts. Muscle Nerve, 12, 401-409.
20. McGeachie, J.K. (1989) Sustained cell proliferation in denervated skeletal muscle of mice. Cell Tissue Res., 257, 455-457.
21. Dorsey, S.G., Lovering, R.M., Renn, C.L., Leitch, C.C., Liu, X., Tallon, L.J., Sadzewicz, L.D., Pratap, A., Ott, S., Sengamalay, N. et al. (2012) Genetic deletion of trkB.T1 increases neuromuscular function. Am. J. Physiol. Cell. Physiol., 302, C141-C153.
22. Khairallah, R.J., Shi, G., Sbrana, F., Prosser, B.L., Borroto, C., Mazaitis, M.J., Hoffman, E.P., Mahurkar, A., Sachs, F., Sun, Y. et al. (2012) Microtubules underlie dysfunction in Duchenne muscular dystrophy. Sci. Signal., 5, ra56.
23. Olojo, R.O., Ziman, A.P., Hernandez-Ochoa, E.O., Allen, P.D., Schneider, M.F. and Ward, C.W. (2011) Mice null for calsequestrin 1 exhibit deficits in functional performance and sarcoplasmic reticulum calcium handling. PLoS ONE, 6, e27036.
24. Lovering, R.M., Michaelson, L. and Ward, C.W. (2009) Malformed mdx myofibers have normal cytoskeletal architecture yet alteredECcoupling and stress-induced Ca2+ signaling. Am. J. Physiol. Cell. Physiol., 297, C571-C580.
25. Homma, S., Chen, J.C.J., Rahimov, F., Beermann, M.L., Hanger, K., Bibat, G.M., Wagner, K.R., Kunkel, L.M., Emerson, C.P. Jr and Miller, J.B. (2012) A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function. Eur. J. Hum. Genet., 20, 404-410.
26. Rahimov, F., King, O.D., Leung, D.G., Bibat, G.M., Emerson, C.P., Kunkel, L.M. and Wagner, K.R. (2012) Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkers. Proc. Natl. Acad. Sci. USA, 109, 16234-16239.
27. Geng, L.N., Yao, Z., Snider, L., Fong, A.P., Cech, J.N., Young, J.M., van der Maarel, S.M., Ruzzo, W.L., Gentleman, R.C., Tawil, R. et al. (2012) DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev. Cell, 22, 38-51.
28. Latil, M., Rocheteau, P., Chatre, L., Sanuli, S., Memet, S., Ricchetti, M., Tajbkhsh, S. and Chretien, F. (2012) Skeletal muscle stem cells adopt a dormant cell state post mortem and retain regenerative capacity. Nat. Commun., 12, 903.
29. Pearson, T., Shultz, L.D., Miller, D., King, M., Laning, J., Fodor, W., Cuthbert, A., Burzenski, L., Gott, B., Lyons, B. et al. (2008) Non-obese diabetic-recombination activating gene-1 (NOD-Rag 1 null) interleukin (IL)-2 receptor common gamma chain (IL2 rg null) null mice: a radioresistant model for human lymphohaematopoietic engraftment. Clin. Exp. Immunol., 154, 270-284.
30. Gabellini, D., D'Antona, G., Moggio, M., Prelle, A., Zecca, C., Adami, R., Angeletti, B., Ciscato, P., Pellegrino, M.A., Bottinelli, R. et al. (2006) Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1. Nature, 439, 973-977.
31. Osborne, R.J., Welle, S., Venance, S.L., Thornton, C.A. and Tawil, R. (2007) Expression profile ofFSHDsupports a link between retinal vasculopathy and muscular dystrophy. Neurology, 68, 569-577.
32. Mitsuhashi, H., Mitsuhashi, S., Lynn-Jones, T., Kawahara, G. and Kunkel, L.M. (2013) Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy. Hum. Mol. Genet., 22, 568-577.
33. Bosnakovski, D., Daughters, R.S., Xu, Z., Slack, J.M. and Kyba, M. (2009) Biphasic myopathic phenotype of mouse DUX, an ORF within conserved FSHD-related repeats. PLoS ONE, 4, e7003.
34. Wallace, L.M., Garwick, S.E., Mei, W., Belayew, A., Coppee, F., Ladner, K.J., Guttridge, D., Yang, J. and Harper, S.Q. (2011)DUX4,a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Ann. Neurol., 69, 540-552.
35. Krom, Y.D., Thijssen, P.E., Young, J.M., den Hamer, B., Balog, J., Yao, Z., Maves, L., Snider, L., Knopp, P., Zammit, P.S. et al. (2013) Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD. PLoS Genet., 9, e1003415.
36. Yokota, T., Lu, Q.L., Partridge, T., Kobayashi, M.,Nakamura, A., Takeda, S. and Hoffman, E. (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann. Neurol., 65, 667-676.
37. Aoki, Y., Yokota, T., Nagata, T., Nakamura, A., Tanihata, J., Saito, T., Duguez, S.M., Nagaraju, K., Hoffman, E.P., Partridge, T. et al. (2012) Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc. Natl. Acad. Sci. USA, 109, 13763-13768.
38. Morrison, B.M., Lachey, J.L., Warsing, L.C., Ting, B.L., Pullen, A.E., Underwood, K.W., Kumar,R., Sako, D., Grinberg, A.,Wong,V. et al. (2009) A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol., 217, 258-268.
39. Li, Z.B., Zhang, J.Y. and Wagner, K.R. (2012) Inhibition of myostatin reverses muscle fibrosis through apoptosis. J. Cell Sci., 125, 3957-3965.
40. Miciak, J.J., Warsing, L.C., Tibbs, M.E., Jasper, J.R., Jampel, S.B., Malik, F.I., Tankersley, C. and Wagner, K.R. (2013) Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model. Muscle Nerve, 48, 279-285.
41. Goodall, M.H., Ward, C.W., Pratt, S.J.P., Bloch, R.J. and Lovering, R.M. (2012) Structural and functional evaluation of branched myofibers lacking intermediate filaments. Am. J. Cell. Physiol., 303, C224-C232.
42. Jones, T.I., Chen, J.C.J., Rahimov, F., Homma, S., Arashiro, P., Beermann, M.L., King, O.D., Miller, J.B., Kunkel, L.M., Emerson, C.P. et al. (2012) Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis. Hum. Mol. Genet., 21, 4419-4430.